EyeBio is a clinical-stage ophthalmology biotech company that brings together an experienced team of leaders, innovators, and entrepreneurs to develop a new generation of therapies for eye diseases. We understand what it takes to establish a new standard of care in ophthalmology. Our co-founders, Dr. David Guyer and Dr. Anthony P. Adamis, created and led the company that introduced the first anti-vascular endothelial growth factor (anti-VEGF) therapy for patients with age-related macular degeneration (AMD).

Based in


Created in

> Website


#Biotech 11.2023


Bain Capital Life Sciences, Omega Funds, Vertex Ventures HC, SV Health Investors, Jeito Capital, Samsara Biocapital & MRL Ventures Fund